Thus, IRF-1 signaling may also be implicated in progression and aggravation of inflammatory bowel diseases by supporting the accumulation of dysregulated NCR+ ILCs, which has been reported in the inflamed gut mucosa in CD43,44. Here, IRF1 is linked to inflammatory bowel disease.